These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 35861645)

  • 1. Severe pemphigoid nodularis successfully treated with dupilumab.
    Jendoubi F; Bost C; Tournier E; Paul C; Konstantinou MP
    Dermatol Ther; 2022 Sep; 35(9):e15727. PubMed ID: 35861645
    [No Abstract]   [Full Text] [Related]  

  • 2. A severe case of IgA bullous pemphigoid successfully treated with dupilumab.
    Valenti M; De Giacomo P; Lavecchia A; Valenti G
    Dermatol Ther; 2022 Nov; 35(11):e15890. PubMed ID: 36181411
    [No Abstract]   [Full Text] [Related]  

  • 3. Dupilumab successfully treated refractory bullous pemphigoid with early clinical manifestations imitating atopic dermatitis: A case letter.
    Zhang Y; Zhang J; Chen J; Lin M; Gong T; Cheng B; Ji C
    Australas J Dermatol; 2021 Nov; 62(4):525-527. PubMed ID: 34448201
    [No Abstract]   [Full Text] [Related]  

  • 4. Hickam versus Ockham: atopic dermatitis and bullous pemphigoid or pemphigoid nodularis? Dupilumab solves the problem.
    Mutton T; Bocchi C; Gaban A; Marzola E; Schettini N; Borghi A
    Ital J Dermatol Venerol; 2024 Jun; 159(3):361-363. PubMed ID: 38695597
    [No Abstract]   [Full Text] [Related]  

  • 5. Case Report: Combination of Omalizumab and Dupilumab for Recalcitrant Bullous Pemphigoid.
    Seyed Jafari SM; Feldmeyer L; Bossart S; Simon D; Schlapbach C; Borradori L
    Front Immunol; 2020; 11():611549. PubMed ID: 33584689
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Dupilumab on Generalized Verrucosis in Refractory Bullous Pemphigoid.
    Wang Q; Ruan Y; Guo F; Zhu H; Pan M
    Acta Derm Venereol; 2023 Sep; 103():adv12324. PubMed ID: 37707294
    [No Abstract]   [Full Text] [Related]  

  • 7. Case report: Dupilumab for the treatment of bullous pemphigoid.
    Wang M; Wang J; Shi B
    Dermatol Ther; 2022 Jul; 35(7):e15541. PubMed ID: 35478478
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful treatment of bullous pemphigoid with dupilumab: a case and brief review of the literature.
    Saleh M; Reedy M; Torok H; Weaver J
    Dermatol Online J; 2021 Apr; 27(4):. PubMed ID: 33999579
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dupilumab for bullous pemphigoid with intractable pruritus.
    Seidman JS; Eichenfield DZ; Orme CM
    Dermatol Online J; 2019 Nov; 25(11):. PubMed ID: 32045153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The treatment of refractory atypical bullous pemphigoid with generalized eczema and intense pruritus with dupilumab.
    Li W; Cai S; Man X
    Dermatol Ther; 2022 Feb; 35(2):e15243. PubMed ID: 34854196
    [No Abstract]   [Full Text] [Related]  

  • 11. Dupilumab for the treatment of pembrolizumab-induced bullous pemphigoid: A case report.
    Pop SR; Strock D; Smith RJ
    Dermatol Ther; 2022 Aug; 35(8):e15623. PubMed ID: 35669992
    [No Abstract]   [Full Text] [Related]  

  • 12. A successful case of vesicular pemphigoid concurrent with pulmonary tuberculosis with dupilumab.
    Shan Y; Zuo YG
    Dermatol Ther; 2022 Apr; 35(4):e15330. PubMed ID: 35080079
    [No Abstract]   [Full Text] [Related]  

  • 13. Clinical Improvement of Bullous Pemphigoid with Hyperkeratosis and Palmoplantar Keratoderma in Two Patients Treated with Dupilumab.
    Pascolini G; Mariotti F; Pira A; Didona B; Di Zenzo G
    Acta Derm Venereol; 2024 Oct; 104():adv41984. PubMed ID: 39387672
    [No Abstract]   [Full Text] [Related]  

  • 14. Dupilumab for the treatment of nivolumab-induced bullous pemphigoid: a case report and review of the literature.
    Klepper EM; Robinson HN
    Dermatol Online J; 2021 Sep; 27(9):. PubMed ID: 34755978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bullous pemphigoid successfully treated with dupilumab.
    Martinez DAES; Periquito AFS; Roa GG; Lupi JP; Treu CM; Lupi O
    An Bras Dermatol; 2024; 99(5):778-780. PubMed ID: 38876965
    [No Abstract]   [Full Text] [Related]  

  • 16. Efficacy and Safety of Dupilumab in Moderate-to-Severe Bullous Pemphigoid.
    Zhang Y; Xu Q; Chen L; Chen J; Zhang J; Zou Y; Gong T; Ji C
    Front Immunol; 2021; 12():738907. PubMed ID: 34721404
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reply to: 'Severe bullous pemphigoid following Covid-19 vaccination resistant to rituximab and successfully treated with dupilumab' by Baffa et al.
    Sun L; Brazão C; Mancha D; Soares-de-Almeida L; Filipe P
    J Eur Acad Dermatol Venereol; 2023 May; 37(5):e578-e580. PubMed ID: 36681888
    [No Abstract]   [Full Text] [Related]  

  • 18. Ixekizumab successfully treated refractory psoriasis concurrent bullous pemphigoid.
    Xiao Y; Gu Y; Xia D; Zhou X; Li W
    J Dermatol; 2023 Feb; 50(2):e76-e78. PubMed ID: 36028948
    [No Abstract]   [Full Text] [Related]  

  • 19. Dupilumab as a novel therapy for bullous pemphigoid.
    Zhang X; Man X; Tang Z; Dai R; Shen Y
    Int J Dermatol; 2023 Apr; 62(4):e263-e266. PubMed ID: 36440691
    [No Abstract]   [Full Text] [Related]  

  • 20. Treatment of Bullous Pemphigoid With Dupilumab: A Case Series of 30 Patients.
    Miller AC; Temiz LA; Adjei S; Duran MA; Sassmannshausen J; Dominguez A; Thomas C; Schmidt JD; Bernhardt M; Doolittle-Amieva CJ; Moshiri AS; Thompson AJ; Pyoung Kim-Lim P; Mattia AV; Tyring SK
    J Drugs Dermatol; 2024 Jun; 23(6):e144-e148. PubMed ID: 38834228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.